The effect of activated factor VII for intracerebral hemorrhage beyond 3 hours versus within 3 hours

Stroke

Volumn 39, Issue 2, 2008, Pages 473-475

  Hallevi, Hen ^a   Gonzales, Nicole R ^a   Barreto, Andrew D ^a   Martin Schild, Sheryl ^a   Albright, Karen C ^b   Noser, Elizabeth A ^a   Illoh, Kachi ^a   Khaja, Aslam M ^a   Allison, Teresa ^c   Escobar, Miguel A ^d   Shaltoni, Hashem M ^a   Grotta, James C ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c MEMORIAL HERMANN HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Hematoma growth; Intracerebral hemorrhage; Recombinant activated factor VII

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; COMPUTER ASSISTED TOMOGRAPHY; CONTROL GROUP; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; HEART INFARCTION; HEMATOMA; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SYMPTOM; THERAPY DELAY; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; LETTER; MIDDLE AGED; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CEREBRAL HEMORRHAGE; COHORT STUDIES; FACTOR VIIA; HEMATOMA; HUMANS; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 39349104592     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.497651     Document Type: Article

References (7)

1. Brott T, Broderick J, Kothari R, Barsan W, Tomsick T, Sauerbeck L, Spilker J, Duldner J, Khoury J. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997;28:1-5.
2. NovoNordisk. Phase 3 stroke trial shows that novoseven® reduces bleeding in the brain, but does not improve long-term clinical outcomes. Stock Exchange Announcement no. 5/2007. 2007.
3. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777-785.
4. Kothari RU, Brott T, Broderick JP, Barsan WG, Sauerbeck LR, Zuccarello M, Khoury J. The ABCs of measuring intracerebral hemorrhage volumes. Stroke. 1996;27:1304-1305.
5. Lisk DR, Pasteur W, Rhoades H, Putnam RD, Grotta JC. Early presentation of hemispheric intracerebral hemorrhage: prediction of outcome and guidelines for treatment allocation. Neurology. 1994;44:133-139.
6. Sugg RM, Gonzales NR, Matherne DE, Ribo M, Shaltoni HM, Baraniuk S, Noser EA, Grotta JC. Myocardial injury in patients with intracerebral hemorrhage treated with recombinant factor VIIa. Neurology. 2006;67:1053-1055.
7. Mayer SA, Brun NC, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T. Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke. 2005;36:74-79.